A New Approach to Assess Drug Development Performance by Rosiello, A. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A New Approach to Assess Drug Development Performance
Citation for published version:
Rosiello, A, Dimitri, N & Fiorini, F 2013, 'A New Approach to Assess Drug Development Performance' Drug
Discovery Today, vol 18, no. 9-10, pp. 420-427. DOI: 10.1016/j.drudis.2013.01.004
Digital Object Identifier (DOI):
10.1016/j.drudis.2013.01.004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Drug Discovery Today
Publisher Rights Statement:
© Rosiello, A., Dimitri, N., & Fiorini, F. (2013). A New Approach to Assess Drug Development Performance.
Drug Discovery Today, 18(9-10), 420-427doi: 10.1016/j.drudis.2013.01.004
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 1 
alessandro.rosiello@ed.ac.uk
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
2 
 
 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
3 
 
 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
4 
INSERT FIGURE 1 ABOUT HERE 
INSERT FIGURE 2 ABOUT HERE 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
5 
 
 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
6 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
7 
 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
8 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
9 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
10 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
11 
 
 
 
 
 
 
 
PLEASE DO NOT CITE WITHOUT PERMISSION. TREAT AS CONFIDENTAL. 
 
 
12 
TABLE 1 
  
phase 
average phase duration 
(months) Pfail Prepeat  Psuccess 
 ph 1 24.0 38.0 41.0 21.0 
Cancer ph 2 33.6 29.0 36.0 35.0 
  ph 3 38.4 35.0 27.0 38.0 
 ph 1 11.2 37.0 43.0 20.0 
Cardiovascular ph 2 19.9 17.0 48.0 35.0 
  ph 3 28.2 20.0 39.0 41.0 
 ph 1 9.5 35.0 37.0 28.0 
CNS ph 2 21.1 17.0 55.0 28.0 
  ph 3 25.4 17.0 45.0 38.0 
 ph 1 9.4 15.0 70.0 15.0 
Dermatology ph 2 16.6 17.0 45.5 37.5 
  ph 3 20.1 3.0 36.0 61.0 
 ph 1 10.1 38.0 31.0 31.0 
Gastrointestinal ph 2 20.1 22.0 32.0 46.0 
  ph 3 27.5 30.0 31.0 39.0 
 ph 1 9.1 27.0 26.0 47.0 
Genitourinary ph 2 23.6 18.0 46.0 36.0 
  ph 3 28.1 17.0 39.0 44.0 
 ph 1 27.7 25.0 41.0 34.0 
Hematological ph 2 30.1 28.0 38.0 34.0 
  ph 3 27.1 15.0 46.0 39.0 
 ph 1 9.5 23.0 60.0 17.0 
Hormonal System ph 2 14.4 19.0 47.0 34.0 
  ph 3 27.5 20.0 50.0 30.0 
 ph 1 12.2 43.0 43.0 14.0 
Immune System ph 2 19.9 24.0 45.0 31.0 
  ph 3 20.2 28.0 24.0 48.0 
Infectious Diseases  
ph 1 12.5 18.0 52.0 30.0 
ph 2 19.6 34.0 36.0 25.0 
ph 3 23.1 18.0 52.0 30.0 
 ph 1 8.0 18.0 46.0 36.0 
Pain ph 2 13.9 12.0 52.0 36.0 
  ph 3 22.9 11.0 37.0 52.0 
 ph 1 16.8 20.0 35.0 45.0 
Musculoskeletal ph 2 18.9 24.0 35.0 41.0 
  ph 3 20.2 25.0 42.0 33.0 
 ph 1 11.7 24.0 38.0 38.0 
Respiratory ph 2 15.5 14.0 55.0 31.0 
  ph 3 21.7 11.0 49.0 40.0 
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TABLE 2  
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AMGEN 2 -1 -1 -1 -1 0 0 -1 -2 0 -1 0 -1 
AMYLIN 0 -1 0 -1 0 0 0 3 0 0 0 -1 0 
BIOGEN 3 4 -1 1 0 0 0 0 -1 -1 0 0 0 
CELGENE 2 0 0 0 -1 0 1 0 -2 0 0 -1 0 
CENTOCOR 2 -1 0 2 0 0 0 0 -1 0 0 1 0 
CEPHALON 2 0 3 0 0 0 0 0 0 0 4 0 0 
CUBIST 0 0 0 0 0 0 0 0 0 2 0 0 0 
ELAN 0 -1 3 0 1 0 0 0 0 1 0 1 0 
ALLERGAN -1 0 2 1 0 2 0 0 1 1 2 0 0 
ENZON 0 0 0 0 0 0 0 0 0 1 0 0 -1 
EXELIXIS 0 -1 -1 0 0 0 0 -1 -1 0 0 0 0 
GENENTECH 3 0 0 0 -1 0 0 1 -1 -1 -1 0 0 
GENZYME 5 -1 0 1 -1 0 -1 2 -3 1 -1 -1 -1 
IMCLONE 1 0 0 0 0 0 0 0 0 0 0 0 0 
MEDIMMUNE 0 0 0 -1 -1 0 -1 0 -3 2 0 -1 0 
MERCK 1 2 -2 -1 -1 3 0 -1 -1 1 0 0 0 
MYRIAD 6 0 1 0 -1 0 0 0 0 0 -1 1 -1 
QLT 0 0 0 -1 0 0 0 0 -1 -1 0 0 0 
REGENERON 0 1 -1 0 -1 0 0 0 -1 0 0 1 0 
TALECRIS 0 0 0 0 0 0 1 -1 2 0 0 0 1 
UNITED 0 4 1 0 0 0 0 1 -1 1 1 0 0 
VERTEX 0 -1 -1 -1 0 0 0 0 -1 1 0 -1 0 
ALKERMES 0 0 0 0 0 -1 0 1 -1 0 0 0 0 
ANLYLAM 0 0 0 0 0 0 0 0 0 0 0 0 0 
ALEXION 0 2 -1 -1 -1 0 0 -1 -1 0 0 -1 0 
INTERMUNE 0 0 0 0 0 0 0 2 0 0 0 0 0 
ISIS 0 -1 0 -2 -1 0 0 2 0 -1 1 0 0 
SALIX 0 0 0 0 4 0 0 0 -1 0 0 -1 -1 
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TABLE 3 
Dependent variable: 
1- Revenues growth per employee (2006-2010):  
 
where revenues are expressed in Million USD. 
Independent  variables: 
1- Ability to deviate in each phase transition  
 
in each therapeutic area, where  is the number of compounds recorded in December 
2009, E  the expected number of compounds one, and  indicates the clinical 
phase. 
2- The firm’s Size: Total Number of Employees (for each firm  at t=2010) 
3- Herfindahl-Hirschman Index (HHI) (economies of scope):  
For each firm  is given by  
 
4- Change over time in R&D spread across therapeutic areas:  
 
5- BIO: 
 
Note that: Index  will refer to the firm, with  
Normalised with respect to: 
- maximum deviation within therapeutic area 
- total compounds developed by each firm 
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Table 4: Regression Models 1 – 2 
MODEL 1  -  INDEPENDENT VARIABLE: Revenue growth per employee (2006-2010) 
DEPENDENT 
VARIABLES 
Coefficient Std. Error T-stat P>t 
95% 
Confidence Interval 
Change R&D Spread 0.9237907  0.4785215 1.93  0.068  -.0743874  1.92196 
HHI 110.3533   56.21752  1.96  0.064  -6.914391 227.621 
BIO 107.2646  51.0375  2.10 0.048  .8022553 213.727 
Deviation Phase 3 330.5004  185.1565  1.78  0.089  -55.72938 716.730 
Constant 46.47229  48.09237  -0.97  0.345  146.7912 -53.8466 
Number of obs 25 
 
F(  4,    20)  3.27 
 Prob > F  0.0324 R-squared 0.3992 
Adj R-squared 0.2743 Root MSE 74.038 
Note that: DEV-Ph1/2_MX and SIZE have been dropped because they were not statistically significant 
MODEL 2 -   INDEPENDENT VARIABLE: Deviation Phase3 
DEPENDENT 
VARIABLES 
Coefficient Std. Error T-stat P>t 
95% 
Confidence Interval 
Deviation Phase 2 0.3723973      0.1524495 2.44  0.023  0.0562363     0.6885582 
HHI -0.0990449      0.0692056     -1.43  0.166  -0.242568     0.0444786 
Constant 0.1411145 0.04211              3.35  0.003  0.0537837 0.2284453 
Number of obs 25 
 
F(  2,    22)  4.82 
 Prob > F  0.0184 R-squared 0.3047 
Adj R-squared 0.2415 Root MSE .39493 
Note that: DEV-Ph1_MX BIO, RD_TA and Size have been dropped because they were not statistically significant 
Table 5: Regression Model 3 
MODEL 3 - DEPENDENT VARIABLE: Revenue growth per employee (2006-2010) 
DEPENDENT 
VARIABLES 
Coefficient 
Robust 
Std. Error T-stat P>t 
95% 
Confidence Interval 
Change R&D spread 1.2606  0.4672232 2.70  0.014  0.2860351  2.2352 
HHI 137.5516   48.24703                      2.85  0.010  36.91005      238.1931 
BIO 166.5349                   69.34919                     2.40 0.026  21.87506      311.1948 
Deviation Phase 3 90.7212                 29.42575                     3.08  0.006  29.34018      152.102 
CONSTANT -107.5269                 56.27525                    -1.91                 0.070 -224.915 9.86123 
Number of obs 25 
 
F(  4,    20)  4.52 
 Prob > F  0.0092 R-squared 0.4465 
Root MSE 70.832 Root MSE 70.832 
Breusch-Pagan / Cook-Weisberg test for heteroskedasticity 
HO Constant variance 
 
Variables Fitted value of RPE_610 
 
chi2(1)    5.79 Prob > chi2   0.0161 
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